Postscripts Rx

The global pharmaceutical landscape is undergoing a dramatic transformation, with UK pharma feeling the squeeze from US pricing reforms and tariff threats. This episode dives deep into how the 2022 US Inflation Reduction Act has created a domino effect across international markets, forcing companies to make tough strategic choices about pricing and market access.

When Eli Lilly temporarily suspended shipments of its blockbuster GLP-1 drug Manjaro to the UK in August, it wasn't due to production challenges—it was a deliberate pricing strategy. With Manjaro projected to exceed $5 billion in sales by 2026, the signal to the UK's National Health Service was clear: current reimbursement models aren't sustainable in this new global pricing reality. The situation has deteriorated to the point where Novartis UK's managing director recently declared the country "largely uninvestable" for pharmaceutical innovation.

At the heart of this crisis lies the UK's Voluntary Scheme for Branded Medicines Pricing and Access, which requires pharma companies to reimburse approximately 27% of net sales to the NHS—the highest rate in Europe. Add Brexit complications that have increased market launch times by 12-16 weeks and compliance costs by 20%, and you have a perfect storm threatening patient access to innovative therapies.

For pharma brand managers, access teams, and innovation leaders, this new landscape demands strategy recalibration. Global launch sequencing will increasingly prioritize markets with predictable pricing environments, while digital companion tools that demonstrate improved outcomes will become essential in negotiating value-based agreements. The future belongs to companies that can think globally while navigating local market complexities, leveraging data to demonstrate value, and maintaining transparent communication with patients caught in the middle of these pricing battles.

Curious about how these global pricing shifts will affect patient access and the future of pharmaceutical innovation? Subscribe to Postscripts for ongoing insights into the changing landscape of healthcare delivery and pharmaceutical strategy.

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

The gap between receiving a prescription and achieving successful treatment outcomes remains one of healthcare's biggest challenges. In this illuminating conversation with Ryan Janvion, VP of Sales and Partnerships at Medisafe, we explore how digital health platforms are revolutionizing patient support after that crucial first prescription.

Drawing from his unique background as a college football player at Wake Forest and former Patriots scouting coordinator, Janvion brings a fresh perspective to pharmaceutical patient engagement. He reveals how pharma companies are pivoting away from building in-house digital solutions to partnering with specialized platforms that better understand patient behavior and preferences. "Pharma has awakened to the idea that they need to invest more in what happens beyond that initial script," Janvion explains, highlighting the industry's growing recognition that medication adherence demands ongoing support.

The discussion takes a fascinating turn when examining how personalization drives better outcomes. Just as coaches tailor their approaches to different athletes, digital health platforms customize support based on individual patient needs - from "drill sergeant" reminders to gentler encouragement. With over 13 years of experience and billions of data points, Medisafe has refined its approach to engaging patients without overwhelming them. The platform serves as a "digital front door" connecting patients to copay assistance, nurse educators, and other support services when they need them most.

Looking toward the future, Janvion predicts growing adoption of PDURs (prescribing digital therapeutics alongside medications) and increased integration across the healthcare ecosystem. As price transparency regulations reshape pharmaceutical competition, brand loyalty fostered through digital engagement will become increasingly valuable.

Whether you're a pharma marketer, digital health innovator, or healthcare provider, this conversation offers crucial insights into creating patient-centered support systems that drive better outcomes. Subscribe now to join our exploration of what happens after the script is written - where the real work of patient care begins.

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

Pharmaceutical manufacturing is undergoing a seismic shift, and Amgen's latest $550 million investment in a cutting-edge biotech research facility in California marks a pivotal moment in this transformation. This bold move signals far more than corporate expansion—it represents a fundamental rethinking of how and where medications are developed and produced in a post-pandemic world.

The stakes couldn't be higher. When oncology medication supply chains from India were disrupted just two years ago, American cancer patients missed critical treatments. During the pandemic, over 80% of US health systems reported drug shortages affecting patient care. These aren't just supply chain statistics; they're stories of real patients whose treatment journeys were compromised by geographic distance and fragile global networks.

Amgen's investment aligns perfectly with emerging policy incentives that fast-track regulatory approvals for companies committing to domestic production. For pharmaceutical marketers, this creates powerful new narratives around supply reliability and "Made in USA" messaging that can drive brand loyalty. Patient support teams gain the ability to coordinate more seamlessly with manufacturing, reducing the friction points that frustrate patients and providers. Digital health platforms like Medisafe become even more valuable, creating tighter feedback loops between patient experiences and production facilities.

The implications extend throughout pharma operations. Procurement teams can negotiate more effectively with shortened lead times and greater transparency. R&D gains proximity to actual patient usage patterns. The entire pharmaceutical value chain evolves from disconnected global segments into an integrated ecosystem that stretches "from the molecule to the mobile device."

Want to understand how these manufacturing shifts will transform patient care and pharmaceutical strategy? Subscribe to Postscripts for ongoing insights at the intersection of pharma innovation, technology, and patient impact. The pharmaceutical landscape is changing—make sure your organization is positioned to thrive in this new era of domestic production and enhanced supply chain resilience.

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

What happens when the medications patients need simply aren't available? The answer is playing out right now across healthcare systems worldwide as pharmaceutical supply chains face unprecedented pressures.

The pharmaceutical industry stands at a crossroads as discussions around a potential 200% tariff on imported drug products force executives to confront uncomfortable truths about supply chain vulnerability. With China providing approximately 40% of active pharmaceutical ingredients used in American medications and 72% of manufacturing facilities located overseas, the stakes couldn't be higher. This isn't merely a procurement challenge—it's a strategic threat that touches every aspect of patient care.

The 2023 chemotherapy shortage offers a sobering glimpse into what happens when supply chains fail. Hundreds of hospitals faced critical shortages of common cancer treatments, forcing doctors to make impossible choices about rationing life-saving medications. This wasn't an isolated incident—over 300 drugs were in active shortage during that period, the highest number in nearly a decade. For patients awaiting treatment, supply chain disruptions quickly became life-threatening realities.

Forward-thinking pharmaceutical companies are responding by building redundancy into their operations, investing in predictive analytics to anticipate disruptions, equipping patient support teams with digital communication tools, and conducting rigorous scenario planning. The percentage of pharma leaders who view supply chain risk as a top strategic threat has jumped from 12% to 42% in just four years—a testament to the growing recognition that supply chain security directly impacts patient outcomes.

Subscribe to Postscripts for more insights at the intersection of pharmaceutical innovation, technology, and patient care. How is your organization preparing for the next supply chain disruption?

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

Healthcare is undergoing a pricing revolution that will fundamentally transform how pharmaceutical companies connect with patients. The new Most Favored Nation model means Medicare will soon pay no more than the lowest price pharmaceutical companies charge in other developed nations – a dramatic shift from America's historical position as the world's most lucrative medication market.

What happens when price is no longer your competitive advantage? This pivotal moment demands pharmaceutical companies rethink their approach to patient relationships. With transparency revealing actual medication costs to both doctors and patients, and shocking statistics showing 57% of patients switch brands or abandon therapy within 90 days, maintaining loyalty becomes critical. The post-prescription experience – what happens after a patient leaves the pharmacy – emerges as the new battleground.

Digital engagement platforms like Medisafe are proving their worth as strategic assets in this changing landscape. By delivering personalized interventions at precisely the right moments, these solutions can improve adherence by 20-30% among active users. The most effective approaches create comprehensive ecosystems acknowledging that patients typically manage multiple medications simultaneously, offering integrated support that includes medication management, educational content, copay assistance, and direct communication channels with healthcare teams. When seven out of ten users engage daily, these platforms become powerful tools for preserving revenue and improving outcomes.

Forward-thinking pharmaceutical companies are already adapting their strategies, investing in U.S. manufacturing and accelerating adoption of digital patient support infrastructures. The fundamental question has shifted from how to launch successfully to how to foster lasting patient relationships throughout the entire treatment journey. When medications are priced similarly, the experience surrounding them becomes the true differentiator – transforming pharmaceutical companies from mere medication providers into genuine patient partners committed to better health outcomes.

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

Loneliness isn't merely an emotional challenge—it's a clinical emergency hiding in plain sight. The latest research reveals a startling truth: feeling isolated carries the same health risks as smoking 15 cigarettes daily, profoundly impacting medication adherence and treatment outcomes for millions with chronic conditions.

A groundbreaking study from Playo and Pure Spectrum uncovers the alarming connection between social isolation and health management. Among 2,000 adults with chronic conditions, 81% report their health status contributes to loneliness, while 52% struggle with medication adherence specifically due to feeling alone. Most concerning, nearly half required emergency care for life-threatening events directly linked to isolation-related care management failures. For specialty medication patients, the statistics are even more troubling—80% experience increased loneliness after diagnosis, with 70% failing to take medications as prescribed.

What makes this crisis particularly challenging is that patients aren't seeking more clinical information—they're desperately craving human connection. Only 10% turn to healthcare providers during their loneliest moments, instead seeking comfort from family or online communities. Yet when offered peer support options, 70% express enthusiasm, with 89% believing such programs would reduce their loneliness and 72% reporting they would improve their medication adherence. This represents a critical opportunity for pharmaceutical companies to reimagine patient support beyond traditional educational materials.

Innovative solutions are emerging that blend technology with authentic human connection. Programs like Medisafe's Care Connector and Voice-activated agent, alongside Playo's Good Start program, demonstrate how empathy can be integrated into the patient journey at critical moments. These approaches don't just improve adherence metrics—they enhance quality of life while reducing healthcare utilization costs. 

Ready to transform how you support patients beyond the prescription? Listen now to discover how addressing the loneliness epidemic could be the missing piece in your patient support strategy, driving breakthrough improvements in adherence, outcomes, and quality of life for those who need it most.

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

The bumpy road to drug pricing reform continues as the US Most Favored Nation deadline of September 29th faces delays. Regulatory complexities, competing healthcare priorities like the Strategic API Reserve, and election year politics are all contributing factors that may push implementation into 2024 or beyond.

• MFN model would force Medicare to pay the lowest drug prices available in other economically comparable countries
• Americans currently pay nearly 250% more for medications than citizens in 32 other developed nations
• Pharma manufacturers argue pricing parity could disincentivize R&D and reduce availability of breakthrough treatments
• Regulatory delays announced as the proposal must pass through review and public comment periods
• New Strategic Active Pharmaceutical Ingredients Reserve initiative may be drawing legislative focus away from pricing reform
• 70% of API manufacturing occurs overseas, mainly in India and China
• Election year politics may prefer to defer enforcement while using the MFN narrative for campaign momentum
• International reference pricing likely to become more common in US payer negotiations
• Digital companions and patient support platforms that demonstrate improved outcomes will be crucial for showing value
• Commercial teams should prepare contingency plans rather than waiting for formal announcements

If you found this conversation valuable, please follow or subscribe for more insights at the intersection of pharma, tech, and patient impact.

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

Cathy is the Sr. Director of Product Marketing at Medisafe, driving marketing efforts that make patients the center of digital solutions that make a difference. 

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

The clock is ticking for pharmaceutical companies as the September 29 deadline for most favored nation pricing plans looms just 47 days away. This sweeping policy shift represents one of the most significant pricing reforms in recent history, with profound implications for everyone from brand marketers to patient access teams.

Five major developments are converging to reshape the pharmaceutical landscape. First, government price negotiations are accelerating, targeting high-cost drugs without generic competition much earlier than originally projected. The Congressional Budget Office estimates these negotiations could save Medicare over $100 billion in the next decade. Second, the July 27 US-EU drug pricing deal introduces shared reference pricing models that could fundamentally alter global launch sequences and reimbursement ceilings. Third, new domestic manufacturing incentives offer substantial benefits for companies shifting production to the United States, including tax credits and expedited regulatory reviews, though potential tariff increases on imported medications could create new affordability challenges.

The fourth development involves comprehensive PBM reform that mandates transparent rebate reporting and price disclosure at the point of care. This increased transparency creates opportunities for patient service teams to better understand cost barriers in real-time and develop targeted interventions. Finally, recent adjustments following a Supreme Court ruling on Medicare Part B reimbursement could lead hospitals serving low-income populations to remove expensive therapies from their formularies, creating unpredictable access obstacles for specialty treatments.

As these changes converge, the healthcare system stands at a critical crossroads of affordability, innovation, and access. Forward-thinking pharmaceutical teams that integrate pricing, access, digital, and commercial strategies will be best positioned to navigate this new terrain. Digital health solutions that monitor treatment irregularities, enable proactive patient support, and leverage predictive analytics will become increasingly valuable tools for identifying and addressing barriers before they lead to treatment abandonment. How will your organization respond to these unprecedented changes? Subscribe to Post-Rifle for ongoing insights at the intersection of pharma, technology, and patient impact.

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

The pharmaceutical industry faces a transformative shift as drug pricing pressures intensify in the US market, with the September 29 deadline approaching for companies to implement Most Favored Nation pricing. Marketing strategies must evolve from traditional branding to outcomes-based approaches that demonstrate real value as margins tighten and price becomes a non-negotiable factor.

• Marketing budgets shifting toward outcome-based strategies that demonstrate improved adherence and access
• Real-world evidence emerging as critical currency to justify medication value beyond scientific efficacy
• Brand differentiation increasingly dependent on patient experience rather than price points
• Product lifecycle marketing accelerating to establish strong launch momentum before price erosion
• Growing investment in adherence programs to maximize value from each prescription
• Patient-centric pricing narratives focusing on equity, access and affordability becoming essential
• Multi-channel personalization delivering 54% higher engagement metrics through targeted communications

If you found this conversation valuable, follow or subscribe for more insights as we keep an eye on the intersection of pharma tech and patient impact. The real work begins after the script is written.

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.